Cytokines and T2D in Egyptian diabetic patients
Not Applicable
- Conditions
- Diabetes T2Nutritional, Metabolic, Endocrine
- Registration Number
- PACTR201801002776119
- Lead Sponsor
- none
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
50 T2D-free controls and 100 patients diagnosed with type 2 diabetes and on any of the oral hypoglycemic agents will be recruited.T2D-free controls enrolled in the study had no type I or II diabetes.
Exclusion Criteria
Patients with infectious diseases, autoimmune disorders, asthma, eczema, allergies, thyroid diseases, kidney failure, liver dysfunction and alcohol abuse will be excluded from the study. In addition, patients who underwent medication changes during the 2 months preceding participation will be also excluded from the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The association between IL-17,IL-18, IL-23,IL-10,IL-37 and IL-35 production and glycemic control of T2D in Egyptian patients were elucidated.
- Secondary Outcome Measures
Name Time Method the association between diabetic clinical complications of T2D and inflammatory cytokines were observed